Results 1 to 10 of about 665,294 (217)

Aromatase Inhibitor-Associated Musculoskeletal Syndrome: Understanding Mechanisms and Management

Frontiers in Endocrinology, 2021
Aromatase inhibitors (AIs) are a key component in the chemoprevention and treatment of hormone receptor-positive (HR+) breast cancer. While the addition of AI therapy has improved cancer-related outcomes in the management of HR+ breast cancer, AIs are ...
Tara Hyder, Christopher C. Marino, Sasha Ahmad, Azadeh Nasrazadani, Adam M. Brufsky   +4 more
doaj   +3 more sources

Long term effects of aromatase inhibitor treatment in patients with aromatase excess syndrome [PDF]

Frontiers in Endocrinology
IntroductionAromatase excess syndrome (AEXS) is a rare, autosomal dominant disorder, characterized by enhanced aromatization of androgens and estrogen excess.
Eleni Z. Giannopoulou, Eleni Z. Giannopoulou, Stephanie Brandt, Stephanie Brandt, Stephanie Brandt, Stefanie Zorn, Stefanie Zorn, Stefanie Zorn, Christian Denzer, Christian Denzer, Julia von Schnurbein, Julia von Schnurbein, Maki Fukami, Alexander Kaiser, Martin Schmidt, Martin Wabitsch, Martin Wabitsch, Martin Wabitsch   +17 more
doaj   +2 more sources

The association between endocrine therapy use and osteoporotic fracture among post-menopausal women treated for early-stage breast cancer in Ontario, Canada

Breast, 2021
Background: The use of endocrine therapy for early-stage breast cancer, particularly aromatase inhibitor therapy has been associated with an increased risk of osteoporosis and fracture in clinical trials.
Phillip S. Blanchette, Melody Lam, Britney Le, Lucie Richard, Salimah Z. Shariff, Alexandra M. Ouédraogo, Kathleen I. Pritchard, Jacques Raphael, Ted Vandenberg, Ricardo Fernandes, Danielle N. Desautels, Kelvin K.W. Chan, Craig C. Earle   +12 more
doaj   +1 more source

The HeyL-Aromatase Axis Promotes Cancer Stem Cell Properties by Endogenous Estrogen-Induced Autophagy in Castration-Resistant Prostate Cancer

Frontiers in Oncology, 2022
Treatment of patients with castration-resistant prostate cancer (CRPC) remains a major clinical challenge. We previously showed that estrogenic effects contribute to CRPC progression and are primarily caused by the increased endogenous estradiol produced
Qimei Lin, Jiasong Cao, Jiasong Cao, Xiaoling Du, Kuo Yang, Yongmei Shen, Yongmei Shen, Weishu Wang, Helmut Klocker, Jiandang Shi, Jiandang Shi, Ju Zhang   +11 more
doaj   +1 more source

SERPINA3-ANKRD11-HDAC3 pathway induced aromatase inhibitor resistance in breast cancer can be reversed by HDAC3 inhibition

Communications Biology, 2023
Endocrine resistance is a major challenge for breast cancer therapy. To identify the genes pivotal for endocrine-resistance progression, we screened five datasets and found 7 commonly dysregulated genes in endocrine-resistant breast cancer cells. Here we
Jing Zhou, Mengdi Zhu, Qi Wang, Yiyuan Deng, Nianqiu Liu, Yujie Liu, Qiang Liu   +6 more
doaj   +1 more source

A REGENERATIVE APPROACH TO AN ACUTE EXACERBATION OF HIP PAIN FROM AROMATASE INHIBITOR ASSOCIATED MUSCULOSKELETAL SYNDROME AND AROMATASE-INHIBITOR ARTHRALGIAS

Journal of Cancer Rehabilitation, 2022
Background Despite aromatase inhibitors (AIs) promising outcomes in breast cancer treatment, aromatase inhibitor-associated musculoskeletal syndromes (AIMSS) and aromatase inhibitor arthralgias (AIAs) are common side effects, due to the hypoestrogenic ...
Christian Vangeison, Colton Reeh, Daniel Briggi, Royce Copeland, George Polson, Emanuel N. Husu   +5 more
doaj   +1 more source

Preparation of a novel antiserum to aromatase with high affinity and specificity: Its clinicopathological significance on breast cancer tissue. [PDF]

PLoS ONE, 2017
Aromatase inhibitors have been widely used for the endocrine treatment of estrogen-dependent breast cancer in postmenopausal patients. However, clinicopathological studies of aromatase have been limited due to unsatisfactory specificity and/or restricted
Naoki Kanomata, Shiro Matsuura, Tsunehisa Nomura, Junichi Kurebayashi, Taisuke Mori, Jo Kitawaki, Takuya Moriya   +6 more
doaj   +1 more source

Shear wave elastography detects novel imaging biomarkers of aromatase inhibitor–induced joint pain: a pilot study

Journal of Ultrasonography, 2021
Aim: To determine whether differences in joint and tendon stiffness as measured by ultrasound shear wave elastography are present in breast cancer patients with aromatase inhibitor-associated arthralgias compared to age-comparable healthy control women ...
Martinez Jessica A., Taljanovic Mihra S., Witte Russell S., Nuncio Zuniga Andres A., Wertheim Betsy C., Kwoh C. Kent, Goldstein Brian A., Roe Denise J., Chalasani Pavani   +8 more
doaj   +1 more source

Construction and validation of a risk prediction model for aromatase inhibitor-associated bone loss

Frontiers in Oncology, 2023
PurposeTo establish a high-risk prediction model for aromatase inhibitor-associated bone loss (AIBL) in patients with hormone receptor-positive breast cancer.MethodsThe study included breast cancer patients who received aromatase inhibitor (AI) treatment.
Meiling Chu, Yue Zhou, Yulian Yin, Lan Jin, Hongfeng Chen, Tian Meng, Binjun He, Jingjing Wu, Meina Ye   +8 more
doaj   +1 more source

Aromatase expression increases the survival and malignancy of estrogen receptor positive breast cancer cells. [PDF]

PLoS ONE, 2015
In postmenopausal women, local estrogen produced by adipose stromal cells in the breast is believed to support estrogen receptor alpha (ERα) positive breast cancer cell survival and growth.
Keya De Mukhopadhyay, Zhao Liu, Abhik Bandyopadhyay, Nameer B Kirma, Rajeshwar R Tekmal, Shui Wang, Lu-Zhe Sun   +6 more
doaj   +1 more source